News
A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...
The FDA sent out "100 cease-and-desist letters" to brands in response to what it says is "deceptive" pharma advertising - which could massively impact pharma's $7 billion U.S. national TV ad ...
Novo Nordisk A/S is poised for long-term growth despite job cuts and margin resets. Click here to find out why NVO stock is a ...
Cigna (CI) reports flat employer coverage rates for obesity drugs like Wegovy from Novo Nordisk (NVO) and Zepbound from Eli ...
GLP-1 medications like Ozempic show promise for multiple health conditions, as experts explore microdosing benefits for blood ...
After struggling to find relief, GLP-1s were the "miracle solution" to their PCOS symptoms. But without insurance coverage, many can't afford them.
CVS Caremark is facing a lawsuit after being accused of pointing patients to use a weight loss drug called Wegovy and for ...
5h
Fox Business on MSNOzempic maker to cut thousands of jobs
The Danish pharmaceutical company will reduce its 78,400-person workforce by approximately 9,000 positions to streamline ...
In response to what it says is "deceptive" pharmaceutical ads, the FDA sent out "100 cease-and-desist letters" to brands - a move that could have massive impact on pharma's $7 billion U.S. national TV ...
Novo Nordisk , the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to ...
A new class-action lawsuit alleges CVS Caremark unlawfully changed its coverage for popular GLP-1 drug Zepbound. | A new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results